Literature DB >> 4035618

Further experience of Corynebacterium parvum in malignant pleural effusion.

D T McLeod, P M Calverley, J W Millar, N W Horne.   

Abstract

The outcome of drug induced pleurodesis has been evaluated in a non-randomised retrospective study of 67 patients with recurrent malignant pleural effusions treated during 1976-83. Fourteen died within 30 days of treatment. Of the remaining 53 patients, 26 studied during 1976-80 were treated with intrapleural mustine hydrochloride, while 27 studied during 1978-83 were treated with intrapleural Corynebacterium parvum. There was no significant difference between the groups in age, sex, or tumour type, most tumours being secondary to bronchial neoplasms. Corynebacterium parvum successfully prevented reaccumulation of the effusion in 24 (92%) patients, while mustine was effective in only 17 (65%) (p less than 0.05). Data on survival were obtained on 47 cases where a single agent was used to induce pleurodesis. In 25 patients treated with C parvum the mean survival was 251 (range 31-1143) days, compared with 119 (range 31-380) days for the 22 patients in whom mustine was used. Survival of the C parvum group was significantly greater (p less than 0.01). The difference was principally due to the greater number of long term survivors in the C parvum group, nine of this group living for more than 180 days (mean 574, range 180-1143 days) compared with only four such survivors in the mustine group (mean 263, range 193-380 days). This study confirms our initial impression that C parvum is highly effective in controlling recurrent malignant pleural effusions. The finding of unexpected long term survivors with C parvum treatment suggests that this treatment may have an additional effect on the progression of disease, a finding that merits further investigation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4035618      PMCID: PMC460123          DOI: 10.1136/thx.40.7.515

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Carcinomatous involvement of the pleura: an analysis of 96 patients.

Authors:  B Chernow; S A Sahn
Journal:  Am J Med       Date:  1977-11       Impact factor: 4.965

2.  The significance of a cytologically negative pleural effusion in bronchogenic carcinoma.

Authors:  D A Decker; D E Dines; W S Payne; P E Bernatz; P C Pairolero
Journal:  Chest       Date:  1978-12       Impact factor: 9.410

3.  Intrapleural tetracycline for control of malignant pleural effusion: a preliminary report.

Authors:  R M Rubinson; H Bolooki
Journal:  South Med J       Date:  1972-07       Impact factor: 0.954

4.  Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis.

Authors:  G R Jones
Journal:  Thorax       Date:  1969-01       Impact factor: 9.139

5.  Malignant pleural effusions.

Authors:  D P Dhillon; S G Spiro
Journal:  Br J Hosp Med       Date:  1983-06

6.  The treatment of malignant pleural effusions by closed trocar tube drainage.

Authors:  C J Lambert; H H Shah; H C Urshel; D L Paulson
Journal:  Ann Thorac Surg       Date:  1967-01       Impact factor: 4.330

7.  Treatment of recurrent pleural effusion by pleurodesis with quinacrine. Comparison between instillation by repeated thoracenteses and by tube drainage.

Authors:  G Stiksa; R Korsgaard; B G Simonsson
Journal:  Scand J Respir Dis       Date:  1979-08

8.  Intracavitary bleomycin in the management of malignant effusions.

Authors:  W Paladine; T J Cunningham; R Sponzo; M Donavan; K Olson; J Horton
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

9.  Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions.

Authors:  J W Millar; A M Hunter; N W Horne
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

  9 in total
  4 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Management of malignant pleural effusion.

Authors:  P T Reid; R M Rudd
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

3.  Prolonged fever after pleural instillation of Corynebacterium parvum (Coparvax).

Authors:  C M Laroche; M Britton
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

4.  Corynebacterium parvum for malignant pleural effusions.

Authors:  V Foresti
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.